Dr. James Yu-Chih Tsai, MD

Dr. Tsai practices at Ava Vascular Surgery Center in Murrieta, California.

Dr. Tsai's NPI, 1437152857, was assigned on May 31, 2005. Dr. Tsai graduated from St. George's University School of Medicine in 1997. Dr. Tsai holds California license A70963.

Dr. Tsai's primary practice is Ava Vascular Surgery Center, at 25485 Medical Center Dr, Murrieta, CA 92562 in Riverside County. The practice phone is (951) 574-6500.

Dr. Tsai's primary practice is Ava Vascular Surgery Center in Murrieta, California. Dr. Tsai is also affiliated with Loma Linda University Medical Center - Murrieta. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Dr. Tsai to 1 more hospital, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tsai practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tsai's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tsai is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Tsai's licenses on file in 4 states: California, Rhode Island, New Jersey and New York.

CMS data shows 18,115 Medicare services from Dr. Tsai across 20 procedure codes in 2024, for 320 Medicare patients. Medicare paid $374,573 for them. Every service was in an office.

CMS counts 320 Medicare patients who saw Dr. Tsai in 2024. The largest group is 65 to 74, with 162 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tsai's median patient age at 62, with 67% women.

In 2024, Dr. Tsai wrote 991 Medicare Part D claims for 118 patients. 81% of them were for generic drugs. CMS names the drug for 754 of them, across 32 drugs with 11 or more claims each, at $903,203 in total drug cost. In 2023, CMS named 833 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Tsai for performance year 2024, reported individually. Dr. Tsai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tsai as offering telehealth.

Dmand AI links 18 papers to Dr. Tsai, published from 2002 to 2023. The most frequent topics are Antineoplastic Agents, Adenocarcinoma and Cell Line, Tumor. Dr. Tsai has published most often in Cancer Invest. Dr. Tsai's most frequent co-authors are Chung-Tsen Hsueh, MD, Meera R. Hameed, MD and Maheswari Senthil, MD.

CMS Open Payments shows 283 general payments to Dr. Tsai from 44 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 86% of the total. Novartis Pharmaceuticals Corporation paid the most, $642.

Dr. Tsai graduated from St. George's University School of Medicine in 1997.

Dr. Tsai is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.